NBDF/ LinkedIn
Aug 31, 2025, 07:31
Avatrombopag Shows Promise for Pediatric Immune Thrombocytopenia in Late-Stage Global Trial: NBDF
National Bleeding Disorders Foundation shared on LinkedIn:
“Promising news for children and adolescents living with immune thrombocytopenia (ITP). A late-stage global trial shows avatrombopag, an oral treatment already approved for adults, can significantly improve platelet counts and reduce bleeding symptoms in pediatric patients, offering a potential new treatment option for an underserved population.
Learn more about the study results and what they could mean for pediatric ITP care in The Lancet Haematology.”
Stay updated with Hemostasis Today.
-
Jun 11, 2026, 23:56Francesco Tannura: Here’s a Graphical Summary of Our Latest Work about CAT
-
Jun 11, 2026, 23:38Why the New 2026 CKM Syndrome Guideline Changes Everything for Chronic Disease Prevention – American College of Cardiology
-
Jun 11, 2026, 23:04ISTH Members Elect the Council Class of 2032
-
Jun 11, 2026, 22:45Tsigereda Bekele: Deep Vein Thrombosis vs Pulmonary Embolism
-
Jun 11, 2026, 22:30Rehan Khan Explores Streptokinase
-
Jun 11, 2026, 16:46Moaz Abouelmagd: Key Findings from a Large Network Meta-Analysis of IV Thrombolytics in Acute Ischemic Stroke
-
Jun 11, 2026, 16:37Wolfgang Miesbach: From Failed Intravitreal Trials to Real Benefit – Subretinal AAV8 Gene Therapy in Pediatric X-Linked Retinoschisis
-
Jun 11, 2026, 16:34Joao Mariano Pego: Advancing Coagulation Diagnostics Through Standardized Thrombin Generation
-
Jun 11, 2026, 16:33Ifeanyichukwu Ifechidere: Nobody Talks About Thrombosis in Sickle Cell Disease